The Coherus Leadership Team

Denny Lanfear
Industry Experience | 27 years
Prior Experience | Amgen, Baxter

Mr. Lanfear has nearly 30 years of biopharmaceutical business experience in technical and leadership roles. He is a 13-year veteran of Amgen. where he was a Corporate Officer and Vice President with broad operational, product development and marketing responsibility. His tenure began in 1986 as a founder of the Process Development Department. Under his 10 year leadership this group became the preeminent process development organization in biopharmaceutical and a key strategic advantage for the company. As Vice President of Process Development and Operations Systems, he directed the business process integration of more than 2,500 operations and quality staff worldwide.

While at Amgen, he also had senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase 3. He reviewed and wrote sections of more than 20 INDs and several BLAs. He managed corporate partner relationships including that with SKB from 1986 to 1990. He also managed and had direct budgetary responsibility for the $135 million development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 Mr. Lanfear was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for Epogen®, a multibillion dollar drug. Prior to joining Amgen, Mr. Lanfear held positions of increasing responsibility at Baxter International.

Mr. Lanfear also was the founder and former CEO of Saronyx, Inc., a drug development software services company with several major biotech clients. In 2005 Mr. Lanfear founded InteKrin Therapeutics and from 2005 to 2010 he was the company’s President and CEO. He became Chairman of the Board in 2010. Under Mr. Lanfear’s five-year leadership a $250 million asset was in-licensed, more than $45 million was raised in venture capital and the company was taken from inception to having a Phase 3 lead product candidate in a major therapeutic area with high market potential.

Mr. Lanfear also is an active life science investor through his firm Lanfear Capital Advisers, which invests in pharmaceutical and medical device companies. He is an investor in and former Director of Anthera Pharmaceuticals, and a former Director of Insmed Therapeutics, a publicly traded company. Lanfear Capital is also Limited Partner in select venture funds.

Mr. Lanfear earned degrees in Biochemistry and Chemical Engineering from Michigan State University and earned his MBA from the Anderson School at UCLA.

View Full Bio

Doug Farrar
Industry Experience | 26 years
Prior Experience | Amgen, Insmed

Mr. Farrar has over 26 years of biotech industry experience, including 18 years with Amgen. He has extensive experience in process development, clinical manufacturing, commercial manufacturing, and his responsibilities have included cell-line development, cell banking, fermentation/cell culture, purification, fill/finish, and lyophilization operations.

Mr. Farrar has been involved in filing 13 Investigational New Drug (IND) Applications and two Biological License Applications (BLAs), and has worked with more than two dozen products produced by recombinant DNA technology in microbial, yeast and mammalian cells. He has managed over $400 million in capital projects and built a process development pilot plant and a multiproduct clinical manufacturing plant from the ground up, as well as expanded, renovated, and retooled commercial manufacturing facilities capable of outputs from hundreds of kilogram to multi-metric tons.

Prior to Coherus Biosciences, Mr. Farrar held the position of Senior Vice President of Pharmaceutical Operations at Insmed Therapeutic Proteins, where he was responsible for process research and development laboratories, manufacturing operations, contract manufacturing operations, logistics, engineering, and maintenance. While at Insmed he successfully developed a line of follow-on biologics, enabling in the sale of the business unit to Merck for $130 million in 2009.

Prior to Insmed, Mr. Farrar worked at Amgen Inc., starting in 1987 in Process Development as an engineer developing, optimizing and scaling-up processes for clinical and commercial production. In 1992, Mr. Farrar took on the role of clinical manufacturing plant manager, producing more than 20 products for use in Amgen clinical trials, seven of which later became commercial products. Mr. Farrar was responsible for the design, construction, and start-up of a new state-of-the-art clinical manufacturing facility to replace an older, smaller one.

In 1998, Mr. Farrar took on the role of plant manager of a large-scale Amgen production facility in Colorado. He successfully transitioned the plant from clinical to an FDA and EMEA licensed commercial production facility while accelerating timelines. Under his guidance, subsequent plant expansion and process improvements significantly increased plant output and capabilities. He has hosted numerous U.S. FDA, European, and Health Canada prior approval and periodic inspections in his production facilities.

Mr. Farrar received his B.S. degree in Chemical Engineering from the University of Missouri Rolla in 1986.

View Full Bio

Barbara Finck, M.D.
Industry Experience | 20 years
Prior Experience | Immunex, PDL Biopharma, NKT Therapeutics, Osprey Pharmaceuticals

Dr. Finck is a board certified rheumatologist with over 20 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings in multiple therapeutic areas. She received her rheumatology training at University of California, San Francisco, where she studied the effects of CTLA4-Ig (subsequently developed and marketed as Orencia®) in a murine lupus nephritis model.

She started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL®. Dr. Finck subsequently has held senior level positions in several biopharmaceutical companies including Immunex (lead medical director for the Phase III clinical development of Enbrel® in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis), Eos Biotechology (VP, Clinical Development) and PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer).

Throughout her career in pharmaceutical development, she has demonstrated her ability to build effective teams and alliances and her passion for developing therapeutics for diseases that represent a significant unmet medical need.

View Full Bio

Craig Halverson
Industry Experience | 30 years
Prior Experience | ZymoGenetics, SciClone

Mr. Halverson has over 30 years of biotechnology industry experience, serving most recently as a Senior Consultant with the Biologics Consulting Group, where he provided strategic quality and regulatory guidance to both multinational and development stage biopharmaceutical companies in the U.S., Europe and Asia.

Prior to BCG, he served as Vice President, Regulatory Affairs and Quality Assurance at SciClone Pharmaceuticals, a commercial stage organization with peptide registrations in over 35 countries. As Vice President of Regulatory Affairs at ZymoGenetics, Mr. Halverson coordinated the successful BLA for recombinant human thrombin and he served as Vice President of Regulatory Affairs and Quality Assurance at Introgen Therapeutics, a gene therapy company.

Mr. Halverson has held positions of increasing responsibility at USC Clinical Laboratories, Hybritech, Baxter BioScience, GenProbe, and CancerVax. In these roles he has coordinated numerous INDs and CTAs supporting multinational clinical trials, successful BLAs and marketing applications, as well as the GXP quality systems infrastructure that supported these organizations.

Mr. Halverson holds a Masters degree in Experimental Pathology from the University of Southern California.

View Full Bio

Alan Herman, Ph.D.
Industry Experience | 30 years
Prior Experience | Genentech, Amgen, Merck, WindRose, Analytica

Dr. Herman has more than 30 years of experience in the biopharmaceutical industry. He started his career at Merck, where he worked on recombinant hepatitis B vaccine. In 1984, he went to Genentech where he worked first in process development and later in pharmaceutics. During his time at Genentech Dr. Herman worked on a number of products, including human growth hormone, tissue plasminogen activator, and interferon.

In 1989 Dr. Herman left Genentech and went to Amgen where he started the Analytical Research and Development Department. During his 11 year leadership this group developed much of the cutting-edge analytics that eventually resulted in a complete reversal of the regulatory view of recombinant products. This new definition of “Well Defined Biological Products” allowed for much more rapid product development and, ultimately, for the entry of biosimilar products to the market. During his tenure at Amgen, his department contributed to over 20 IND’s and several BLA’s.

In 2003, Dr. Herman went to work as Senior Director of Quality Control for Tercica, Inc., a start-up company which had in-licensed a late-stage compound (IGF-1) from Genentech. His primary responsibility was to design a comparability program that would minimize the need for further clinical trials. Dr. Herman’s additional responsibilities were to engage and supervise contract laboratories for product characterization, method development and validation, release testing, and clinical and commercial stability. IGF-1 received a commercial license within two years of company formation.

In 2005, Dr. Herman founded and served as CEO of WindRose Analytica, Inc., a contract analytical laboratory. He brought the company to profitability within two years and established a client base which included several large international pharmaceutical companies. WindRose Analytica quickly gained a reputation as one of the world’s outstanding protein analytical laboratories. In 2009, WindRose Analytica was acquired by Althea Technologies, Inc., resulting in a positive return to the investors. Dr. Herman served as CSO and Vice President of Product Development at Althea until joining Coherus Biosciences in April of 2011.

Dr. Herman received his B.S. and M.S. degrees in biology at Indiana University of Pennsylvania. He received a Ph.D. in protein chemistry from Duke University, and did his post-doctoral work in oncogenic virus structure at Duke University Medical Center under Dr. Dani Bolognesi.

View Full Bio

George G. Montgomery
Industry Experience | 26 years
Prior Experience | Sagent Advisors, Montgomery & Co., JP Morgan H&Q, Cowen & Company, Credit Suisse First Boston

Mr. Montgomery joins Coherus with over 25 years experience in investment banking and healthcare industry leadership. Over his career, he has focused on private and public financings, M&A advisory work, divestitures and negotiating strategic partnerships.

Most recently, Mr. Montgomery was a Managing Director at Sagent Advisors, LLC. Prior to Sagent, he served as a Managing Director at Montgomery & Co., LLC where he led the firm’s healthcare effort and helped open their San Francisco office. During his tenure there, he also served on their Board of Directors and was a member of the executive committee.

Prior to Montgomery & Co., he was a Managing Director at JP Morgan H&Q where he led the firm’s healthcare efforts on the West Coast. He has also been a Managing Director at Cowen & Company and started his career at Credit Suisse First Boston in 1983. George received his MBA from the Wharton School at the University of Pennsylvania and his BA from Yale College.

View Full Bio

Peter Watler, Ph.D.
Industry Experience | 25 years
Prior Experience | Amgen, Hyde, VaxGen

Dr. Watler has over 25 years of biopharmaceutical process development and manufacturing experience, nearly half of which was gained in process development and manufacturing at Amgen. He is highly experienced with the development and scale-up of biopharmaceutical processes including key unit operations such as fermentation, centrifugation, filtration, and chromatography. Dr. Watler brings a strong skillset for process modeling, economic analysis, manufacturing operational excellence, process control and validation. His regulatory experience includes co-authoring two IND submissions, four BLA submissions, and participation in several FDA inspections and GMP audits.

Dr. Watler is a 12-year veteran of Amgen, which he joined in 1990. While at Amgen, he held roles leading process scale-up, manufacturing technical services and pilot plant operations. As Associate Director of Process Engineering, he oversaw the start-up of a 30,000 square foot pilot plant for monoclonal antibody development. In this role he implemented systems to accelerate technology transfer and scale up from the laboratory through to clinical production for over ten product candidates. He also led teams responsible for the process validation of Neupogen®, Stemgen®, Kepivance® and Infergen®.

Dr. Watler most recently served as Chief Technology Officer of Hyde Engineering + Consulting, Inc. He led projects for GMP manufacturing facility design where he employed state-of-the-art technologies to drive down capital costs while enhancing cGMP compliance and operational efficiency. Dr. Watler has presented extensively in the US, Canada, China, Europe and Japan on the latest ICH, FDA and ASTM approaches to pharmaceutical risk management, process validation and Quality by Design.

Dr. Watler was previously Vice President, Manufacturing at VaxGen, a Genenetech spinoff formed to develop an AIDS vaccine. He led the design, construction, and validation of a GMP facility for recombinant vaccine production. This fast-track project featured systems from top tier suppliers and went from design through construction to start-up in just 12 months. Dr. Watler was also responsible for managing supply chain and production operations, led the CMC team and prepared submissions for the FDA, NIH and DHHS. He began his career with Allelix Biopharmaceuticals as a Process Development Engineer optimizing fermentation mass transfer and product harvest operations.

Dr. Walter holds a Bachelors and a Masters degree in Chemical Engineering from the University of Toronto where he developed a prototype implantable insulin pump and a Ph.D. in Chemical Engineering from Yamaguchi University, Japan where he implemented mechanistic modeling techniques for the scale-up and optimization of protein chromatography.

View Full Bio

Coherus: The New Model

The New Model

At Coherus Biosciences, we're pulling apart every link in the value chain to see what we can improve in drug discovery, molecular biology, development, production, clinical trials, manufacturing and launch. The result is a unique, new biotech business model that increases speed-to-market while decreasing costs for safe, high-quality biotherapeutics.

Learn More
Coherus: Science


The bedrock expertise of the Coherus team is our understanding of proteins and their development into medicines. Of the small community of people around the world with significant experience in biotherapeutic products, Coherus Biosciences has a dozen of them on the team.

Learn More